Guardant Health Inc (GH)

Jan 16, 2025, 8:05 AM EST - 1 day ago

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

Jan 14, 2025, 3:56 PM EST - 3 days ago

Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment

Jan 13, 2025, 7:00 AM EST - 4 days ago

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Jan 7, 2025, 8:03 AM EST - 10 days ago

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute's Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

Jan 2, 2025, 4:05 PM EST - 15 days ago

Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 8:05 AM EST - 4 weeks ago

Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

Dec 19, 2024, 6:00 AM EST - 4 weeks ago

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

Dec 18, 2024, 8:05 AM EST - 4 weeks ago

Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

Dec 9, 2024, 8:05 AM EST - 5 weeks ago

Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 1:31 PM EST - 6 weeks ago

Guardant Health Stock Flashing Surefire ‘Buy' Signal

Nov 25, 2024, 5:09 PM EST - 7 weeks ago

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

NTRA

Nov 13, 2024, 5:05 PM EST - 2 months ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2024, 9:53 PM EST - 2 months ago

Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 2 months ago

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Nov 1, 2024, 7:00 AM EDT - 2 months ago

Guardant Health to Participate in Upcoming Investor Conferences

Oct 30, 2024, 9:30 AM EDT - 2 months ago

Guardant Health Named to TIME's List of the Best Inventions of 2024

Oct 28, 2024, 8:05 AM EDT - 2 months ago

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024

Oct 24, 2024, 5:05 PM EDT - 3 months ago

Roberto A. Mignone Joins Guardant Health Board of Directors

Oct 15, 2024, 4:05 PM EDT - 3 months ago

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

Sep 18, 2024, 8:05 AM EDT - 4 months ago

GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long

Sep 13, 2024, 2:00 AM EDT - 4 months ago

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

Sep 10, 2024, 8:00 AM EDT - 4 months ago

Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy

Aug 27, 2024, 4:05 PM EDT - 5 months ago

Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 5:00 PM EDT - 5 months ago

Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening

Aug 7, 2024, 11:59 PM EDT - 5 months ago

Guardant Health, Inc. (GH) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 5 months ago

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Aug 7, 2024, 8:05 AM EDT - 5 months ago

Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer

Aug 1, 2024, 8:30 AM EDT - 6 months ago

Guardant Health's FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Aug 1, 2024, 8:00 AM EDT - 6 months ago

Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies

Jul 30, 2024, 8:14 AM EDT - 6 months ago

Guardant Health's stock up after FDA approves its blood test for colon-cancer screening

Jul 29, 2024, 2:57 PM EDT - 6 months ago

Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test

Jul 29, 2024, 1:21 PM EDT - 6 months ago

FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption

Jul 29, 2024, 10:01 AM EDT - 6 months ago

Guardant Health Shares Rise 7% After FDA Approves Its Blood Test For Colon Cancers

Jul 29, 2024, 6:41 AM EDT - 6 months ago

US FDA approves Guardant Health's blood-based cancer test

Jul 29, 2024, 6:30 AM EDT - 6 months ago

Guardant Health's Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

Jul 24, 2024, 4:05 PM EDT - 6 months ago

Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 23, 2024, 8:05 AM EDT - 6 months ago

Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance

Jul 18, 2024, 5:00 PM EDT - 6 months ago

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Jun 4, 2024, 8:05 AM EDT - 8 months ago

Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

May 31, 2024, 8:05 AM EDT - 8 months ago

Guardant Health Named to TIME100 Most Influential Companies

May 30, 2024, 8:05 AM EDT - 8 months ago

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

May 23, 2024, 7:03 PM EDT - 8 months ago

FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

May 23, 2024, 4:58 PM EDT - 8 months ago

U.S. FDA advisers back approval for Guardant's blood-based cancer test

May 23, 2024, 7:05 AM EDT - 8 months ago

Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening

May 21, 2024, 8:51 AM EDT - 8 months ago

Trinity Industries, Inc. Announces Offering of Additional 7.750% Senior Notes Due 2028

JOBY

May 21, 2024, 8:05 AM EDT - 8 months ago

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

May 16, 2024, 8:05 AM EDT - 8 months ago

Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week

May 10, 2024, 5:56 AM EDT - 9 months ago

Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 9 months ago

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

May 7, 2024, 8:00 AM EDT - 9 months ago

Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone